Emergence of Integrase Resistance Mutations During Initial Therapy Containing Dolutegravir.
- Author(s): Fulcher, Jennifer A
- Du, Yushen
- Zhang, Tian-Hao
- Sun, Ren
- Landovitz, Raphael J
- et al.
Published Web Locationhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6093998/pdf/ciy228.pdf
Dolutegravir (DTG) is a preferred drug for initial treatment of human immunodeficiency virus type 1 infection. We present next-generation sequencing analysis of integrase genotypes during a period of virologic failure in a treatment-naive man who initiated tenofovir disoproxil fumarate/emtricitabine plus DTG.